Skip to main content
SpringerLink
Log in

Prevention and Treatment of Heart Failure in Hypertension Guidelines

  • Chapter
Hypertension and Heart Failure

Part of the book series: Updates in Hypertension and Cardiovascular Protection ((UHCP))

  • 1454 Accesses

Abstract

This chapter focuses on the prevention of heart failure by antihypertensive treatment and treatment of people with hypertension and an established heart failure. On the former issue, the chapter emphasizes that blood pressure-lowering interventions majorly reduce the risk of incipient heart failure, the degree of benefit being similar or even greater than other major benefits associated with a blood pressure reduction, such as prevention of cerebrovascular events. It further emphasizes that the prevention of heart failure by antihypertensive treatment is largely due to blood pressure lowering per se, i.e. regardless of the drug employed, although some differences between drugs (greater and lesser incipient heart failure reduction by diuretics and calcium channel blockers, respectively) may exist. On the latter issue, the chapter reviews the evolving position of guidelines on how to treat patients in whom heart failure is accompanied by uncontrolled blood pressure values. Mention is made of the blockers of the renin-angiotensin system (ACE inhibitors and angiotensin receptor antagonists) and loop diuretics as the preferred drugs together with antialdosterone agents, beta-blockers and calcium channel blockers, the last drugs needed to control angina. It is further mentioned that treatment aimed at reducing blood pressure (1) should start at systolic blood pressure values equal or above 140 mmHg and (2) a target blood pressure can hardly be identified because in heart failure the need to use life-saving and symptomatic drugs that also lower blood pressure may require their administration throughout a wide range of values.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557–62.

    CAS  PubMed  Google Scholar 

  2. Lenfant C, Roccella EJ. A call to action for more aggressive treatment of hypertension. J Hypertens Suppl. 1999;17(1):S3–7.

    CAS  PubMed  Google Scholar 

  3. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, Chalmers J, Rodgers A, Rahimi K. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957–67.

    PubMed  Google Scholar 

  4. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials. J Hypertens. 2014;32(12):2285–95.

    CAS  PubMed  Google Scholar 

  5. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603–15.

    PubMed  Google Scholar 

  6. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, Woodward M, MacMahon S, Turnbull F, Hillis GS, Chalmers J, Mant J, Salam A, Rahimi K, Perkovic V, Rodgers A. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387(10017):435–43.

    PubMed  Google Scholar 

  7. Brunström M, Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med. 2018;178(1):28–36.

    PubMed  Google Scholar 

  8. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels—overview and meta-analyses of randomized trials. J Hypertens. 2014;32(12):2296–304.

    CAS  PubMed  Google Scholar 

  9. Blood Pressure Lowering Treatment Trialists’ Collaboration, Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, Chalmers J, Zanchetti A, MacMahon S. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25(5):951–8.

    Google Scholar 

  10. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs—overview and meta-analyses. J Hypertens. 2015;33(2):195–211.

    CAS  PubMed  Google Scholar 

  12. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2000;283(15):1967–75.

    Google Scholar 

  13. Chapman N, Chang CL, Dahlöf B, Sever PS, Wedel H, Poulter NR, Investigators ASCOT. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation. 2008;118(1):42–8.

    CAS  PubMed  Google Scholar 

  14. Mancia G, Agabiti-Rosei E, Cifkova R, DeBacker G, Erdine S, Fagard R, Farsang C, Heagerty AM, Kawecka-Jaszcs K, Kiowski W, Kjeldsen S, Lüscher T, McInnes G, Mallion JM, Mogensen CE, Brien EO, Poulter NR, Priori SG, Rahn KH, Rodicio JL, Ruilope LM, Safar M, Staessen JA, van Zwieten P, Waeber B, Williams B, Zanchetti A, Zannad F. European Society of Hypertension—European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011–53.

    Google Scholar 

  15. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87.

    CAS  PubMed  Google Scholar 

  16. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC Guidelines for the management of arterial hypertension. J Hypertens. 2013;31:1281–357.

    CAS  PubMed  Google Scholar 

  17. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, MM JJ, Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362(9386):777–81.

    CAS  PubMed  Google Scholar 

  18. Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators, Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372(9644):1174–83.

    Google Scholar 

  19. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, Investigators I-PRESERVE. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456–67.

    CAS  PubMed  Google Scholar 

  20. Williams B, (ESC Chairperson) (UK), Giuseppe Mancia (ESH Chairperson) (Italy), Wilko Spiering (The Netherlands), Enrico Agabiti Rosei (Italy), Michel Azizi (France), Michel Burnier (Switzerland), Denis L. Clement (Belgium), Antonio Coca (Spain), Giovanni de Simone (Italy), Anna Dominiczak (UK), Thomas Kahan (Sweden), Felix Mahfoud (Germany), Josep Redon (Spain), Luis Ruilope (Spain), Alberto Zanchetti (Italy), Mary Kerins (Ireland), Sverre E. Kjeldsen (Norway), Reinhold Kreutz (Germany), Stephane Laurent (France), Gregory Y.H. Lip (UK), Richard McManus (UK), Krzysztof Narkiewicz (Poland), Frank Ruschitzka (Switzerland), Roland E. Schmieder (Germany), Evgeny Shlyakhto (Russia), Costas Tsioufis (Greece), Victor Aboyans (France) and Ileana Desormais (France). The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH) 2018 ESC/ESH Guidelines for the Management of Arterial Hypertension. J Hypertens. 2018;36:1953–2041.

    CAS  PubMed  Google Scholar 

  21. Zanchetti A, Thomopoulos C, Parati G. Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circ Res. 2015;116(6):1058–73.

    CAS  PubMed  Google Scholar 

  22. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs—overview and meta-analyses. J Hypertens. 2015;33(7):1321–41.

    CAS  PubMed  Google Scholar 

  23. SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Oparil S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16.

    Google Scholar 

  24. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension. 2000;35(2):580–6.

    CAS  PubMed  Google Scholar 

  25. Bombelli M, Facchetti R, Carugo S, Madotto F, Arenare F, Quarti-Trevano F, Capra A, Giannattasio C, Dell’Oro R, Grassi G, Sega R, Mancia G. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure vaues. J Hypertens. 2009;27(12):2458–64.

    CAS  PubMed  Google Scholar 

  26. Angeli F, Reboldi G, Poltronieri C, Stefanetti E, Bartolini C, Verdecchia P, MAVI Investigators. The prognostic legacy of left ventricular hypertrophy: cumulative evidence after the MAVI study. J Hypertens. 2015;33(11):2322–30.

    CAS  PubMed  Google Scholar 

  27. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.

    PubMed  Google Scholar 

  28. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Milano-Bicocca, Milan, Italy

    Giuseppe Mancia

  2. Policlinico di Monza, Milan, Italy

    Giuseppe Mancia

Authors
  1. Giuseppe Mancia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Mancia .

Editor information

Editors and Affiliations

  1. Carol Davila University of Medicine and Pharmacy Bucharest and Cardiology Department, Emergency Clinical Hospital, Bucharest, Romania

    Maria Dorobantu

  2. University of Milano-Bicocca, Milano, Italy

    Giuseppe Mancia  & Guido Grassi  & 

  3. Department of Pharmacology, Toxicology and Clinical Psychopharmacology Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

    Victor Voicu

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Cite this chapter

Mancia, G. (2019). Prevention and Treatment of Heart Failure in Hypertension Guidelines. In: Dorobantu, M., Mancia, G., Grassi, G., Voicu, V. (eds) Hypertension and Heart Failure. Updates in Hypertension and Cardiovascular Protection. Springer, Cham. https://doi.org/10.1007/978-3-319-93320-7_25

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-93320-7_25

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-93319-1

  • Online ISBN: 978-3-319-93320-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation